Safety concerns are one of the biggest barriers to starting weight loss medication. Here's what the clinical evidence actually shows.
GLP-1 medications (Wegovy, Mounjaro)
GLP-1 medications have extensive clinical trial data — the STEP programme for semaglutide involved over 15,000 participants, and SURMOUNT for tirzepatide involved over 5,000. Long-term data extends to 4 years for semaglutide.
The most common side effects (nausea, GI issues) are well-documented and manageable. Serious side effects (pancreatitis, gallbladder problems) are rare. The cardiovascular benefits (20% reduction in MACE events) arguably make Wegovy protective rather than risky for heart health.
The risk of NOT treating obesity
Obesity itself carries significant health risks: cardiovascular disease, type 2 diabetes, certain cancers, sleep apnoea, joint problems, and reduced life expectancy. For most eligible patients, the benefits of effective weight loss medication substantially outweigh the risks.
What about long-term safety?
The honest answer: we have 4 years of data for semaglutide and less for tirzepatide. Longer-term effects beyond 4 years are not yet known. Your doctor will monitor you regularly and weigh ongoing benefits against any emerging concerns.
Specific medication safety profiles
| Medication | Years of data | Participants studied | Key safety finding |
|---|---|---|---|
| Semaglutide (Wegovy) | 4+ years | 15,000+ | 20% CV risk REDUCTION (protective) |
| Tirzepatide (Mounjaro) | 2+ years | 5,000+ | No new signals. CV trial ongoing. |
| Phentermine (Duromine) | 60+ years | Extensive | Safe short-term. CV risk with prolonged use. |
| Orlistat (Xenical) | 25+ years | Extensive | Very safe. Minimal systemic absorption. |
The key context
Every medication carries some risk. The question is whether the risk of the medication is less than the risk of untreated obesity. For most eligible patients, the answer is clearly yes. Untreated obesity increases risk of heart disease, stroke, type 2 diabetes, 13 types of cancer, sleep apnoea, and reduced life expectancy. Weight loss medication — particularly GLP-1 agonists — directly reduces many of these risks.
The appropriate stance is informed caution: take the medication under medical supervision, attend regular follow-ups, report any concerning symptoms, and weigh the benefits against your individual risk profile with your doctor.